How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-atherothrombotic-events-in-symptomatic-peripheral-artery-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of atherothrombotic events in symptomatic peripheral artery disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of atherothrombotic events in symptomatic peripheral artery disease (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of atherothrombotic events in symptomatic peripheral artery disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Xarelto	rivaroxaban	Johnson & Johnson	Direct Factor Xa Inhibitor	Factor Xa (FXa)		2011-01-01
Xarelto	Xarelto	University Hospital, Montpellier		Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson · 1 drug in Prevention of atherothrombotic events in symptomatic peripheral artery disease
University Hospital, Montpellier · 1 drug in Prevention of atherothrombotic events in symptomatic peripheral artery disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of atherothrombotic events in symptomatic peripheral artery disease:

Cite this brief

Drug Landscape (2026). Prevention of atherothrombotic events in symptomatic peripheral artery disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-atherothrombotic-events-in-symptomatic-peripheral-artery-disease. Accessed 2026-06-10.

Prevention of atherothrombotic events in symptomatic peripheral artery disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing